TrialAntimicrobial agents and chemotherapy2008

Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.

Fenglei Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.